iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Breast Density
Assessment Software Built on Artificial Intelligence
Nashua, NH – August 8, 2018 – iCAD (Nasdaq: ICAD), a global leader in medical technology providing
innovative cancer detection and therapy solutions, announced today FDA
clearance of its latest Artificial Intelligence software solution; PowerLook
Density Assessment Version 3.4. The software is compatible with iCAD’s digital
breast tomosynthesis (DBT) platform on both GE and Hologic systems, enhancing
the Company’s comprehensive suite of breast health solutions available in a
single platform.
“At iCAD, we continually strive to provide radiologists with the
most advanced, accurate and efficient software solutions designed for the early
detection of breast cancer,” said Ken Ferry, CEO of iCAD. “Breast density plays a critical role in both
risk assessment and accuracy, as mammography
sensitivity is reduced to approximately 48 percent from an average of 98
percent in those women with dense breasts. Our cutting-edge technology rapidly produces
consistent breast density results while reducing the risk of reader
variability, enabling radiologists to more easily identify women who might
benefit from additional screening.”
According to a recent study published in the Annals of
Internal Medicine, between 40-50percent of
women in the United States are considered to
have dense breasts, which can increase tumor aggressiveness, as well as mask
the presence of tumors in a mammogram.
iCAD’s PowerLook Density
Assessment 3.4 delivers automated, rapid and reproducible assessments of breast
density to help identify patients that may experience reduced sensitivity to
digital mammography due to dense breast tissue. This innovative technique,
based on machine learning, calibrates the patient’s breast density to the
appropriate category corresponding to the American College of Radiology’s
Breast Imaging Reporting and Data System (BI-RADS) reporting system.
“Since
implementing PowerLook Density Assessment, our radiologists have been able to
provide more consistent breast density results for our patients during
screenings. We must consider many
aspects of each patient’s case at once, but PowerLook Density Assessment allows
us to focus on our primary goal of finding breast cancer. Density matters and we believe the greater
accuracy of assessment with iCAD’s PowerLook Density Assessment will result in
greater patient satisfaction and improve patient care,” stated Dr.
Beth Ingram, MD, Radiology,
Interventional at Reid Health, Indiana.
About iCAD, Inc.
Headquartered in Nashua, N.H., iCAD is a global medical technology
leader providing innovative cancer detection and therapy solutions. For more
information, visit www.icadmed.com.
“Safe Harbor” Statement under the Private
Securities Litigation Reform Act of 1995
Certain statements contained in this News
Release constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of the
Company to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited to the Company’s ability to defend itself
in litigation matters, to achieve business and strategic objectives, the risks
of uncertainty of patent protection, the impact of supply and manufacturing
constraints or difficulties, uncertainty of future sales levels, protection of
patents and other proprietary rights, product market acceptance, possible
technological obsolescence of products, increased competition, litigation
and/or government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt obligations,
competitive factors, the effects of a decline in the economy or markets served
by the Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,” “demonstrate,”
“intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,”
“seek,” and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contacts:
Media Inquiries:
Paul Barren
855.300.8209 ext 126
paul@arpr.com
or
Investor Relations:
LifeSci Advisors
Jeremy Feffer, (212) 915-2568